FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293506678> ?p ?o ?g. }

• W4293506678 abstract "Yeast-derived β-glucans impact immunity, though their effects on gut permeability and inflammation are less understood. Most research has investigated other components of the yeast cell wall, such as the prebiotic mannan- and fructo-oligosaccharides. The objective of this study was to assess the effects of feeding a concentrated yeast product on markers of inflammation (serum amyloid A [SAA] and haptoglobin [Hp]) and oxidative status (malondialdehyde [MDA]), fecal products of fermentation, and gut permeability. Nineteen privately owned domestic Siberian huskies, and one Alaskan husky (9 females: 5 intact, 4 spayed; 11 males: 3 intact, 8 neutered), with an average age of 4.8 ± 2.6 yr and body weight (BW) of 25.6 ± 4.1 kg, were used in this study. Dogs were blocked and randomly allocated to one of two diet groups. Ten dogs received a dry extruded diet. The other 10 received the same diet top dressed with yeast for a daily β-glucan dose of 7 mg/kg BW for 10 wk. Fecal collection, for evaluation of fecal metabolites, and scoring occurred weekly. Gut permeability was assessed using the chromium-labeled ethylenediamine tetra-acetic acid (Cr-EDTA) and iohexol markers prior to the initiation of dietary treatment and after 10 wk of treatment. Blood samples were collected premarker administration and 0.5, 1, 2, 3, 4, 5, and 6 h postadministration. Fasting concentrations of SAA, Hp, and MDA were measured on weeks -1, 2, 4, and 8. Incremental area under the curve (I-AUC) was calculated for serum iohexol and Cr-EDTA concentrations. All data were analyzed using PROC GLIMMIX of SAS with dog as random effect, and week as fixed effect and repeated measure. Dogs receiving treatment tended to have decreased I-AUC of Iohexol (P = 0.10) and Cr-EDTA (P = 0.06) between baseline and cessation of treatment compared to the change over time in I-AUC for control (Ctl) dogs. Treatment dogs had lower Hp concentrations (P ≤ 0.05) than Ctl. There were no differences between treatments for SAA and MDA concentrations (P > 0.05). Fecal arabinose concentrations were greater in treatment (Trt) dogs (P ≤ 0.05) compared to Ctl, though no other fecal metabolites were affected by treatment. There was no difference in the relative frequency of defecations scored at any fecal score between Trt and Ctl dogs, and mean score did not differ between groups (P > 0.10). These data suggest that concentrated brewer's yeast may have the potential to reduce gut permeability without impacting inflammatory status and markers of health in adult dogs.This study evaluated the effects of concentrated brewer’s yeast on gut health in dogs. Nineteen Siberian Huskies and one Alaskan husky were blocked and randomly allocated to one of two groups. Treatment dogs received a yeast supplement for 10 wk, while control dogs received no supplement. Dogs were administered two markers to assess intestinal permeability prior to start of treatment and following 10 wk of treatment. Blood samples were collected and analyzed for markers of inflammatory status (serum amyloid A [SAA] and Haptoglobin [Hp]) and oxidative status (serum malondialdehyde [MDA]). Fecal samples were collected weekly to assess fecal score as well as fecal metabolite concentrations. Intestinal permeability was reduced in treatment dogs following treatment, and no change was observed in the control group. Treatment dogs had lower Hp concentrations than control (Ctl), but there were no differences between treatments for SAA and MDA. Fecal arabinose concentrations were significantly greater in the treatment group when compared to control. There were no differences in the relative frequency of defecations scored at any fecal score between treatment and Ctl dogs, nor did mean score differ between the groups. This study suggests that concentrated brewer’s yeast may reduce gut permeability and inflammation without detrimentally impacting markers of health in adult dogs." @default.
• W4293506678 created "2022-08-30" @default.
• W4293506678 creator A5004513507 @default.
• W4293506678 creator A5014354602 @default.
• W4293506678 creator A5025229697 @default.
• W4293506678 creator A5031577910 @default.
• W4293506678 creator A5033863509 @default.
• W4293506678 creator A5040460325 @default.
• W4293506678 creator A5075840871 @default.
• W4293506678 creator A5076742331 @default.
• W4293506678 creator A5085979296 @default.
• W4293506678 creator A5086907288 @default.
• W4293506678 creator A5091345962 @default.
• W4293506678 date "2022-08-27" @default.
• W4293506678 modified "2023-09-30" @default.
• W4293506678 title "A proof of principle study investigating the effects of supplemental concentrated brewer’s yeast on markers of gut permeability, inflammation, and fecal metabolites in healthy non-challenged adult sled dogs" @default.
• W4293506678 cites W1576632376 @default.
• W4293506678 cites W1782117607 @default.
• W4293506678 cites W1858820873 @default.
• W4293506678 cites W1905504015 @default.
• W4293506678 cites W1969082433 @default.
• W4293506678 cites W1975278282 @default.
• W4293506678 cites W1988679192 @default.
• W4293506678 cites W1988940275 @default.
• W4293506678 cites W1991642690 @default.
• W4293506678 cites W1994603967 @default.
• W4293506678 cites W2001957736 @default.
• W4293506678 cites W2008669100 @default.
• W4293506678 cites W2013145985 @default.
• W4293506678 cites W2017349897 @default.
• W4293506678 cites W2028462429 @default.
• W4293506678 cites W2032181629 @default.
• W4293506678 cites W204319588 @default.
• W4293506678 cites W2059344017 @default.
• W4293506678 cites W2066918820 @default.
• W4293506678 cites W2072301438 @default.
• W4293506678 cites W2073713480 @default.
• W4293506678 cites W2076218968 @default.
• W4293506678 cites W2078874780 @default.
• W4293506678 cites W2084995727 @default.
• W4293506678 cites W2089486469 @default.
• W4293506678 cites W2090855216 @default.
• W4293506678 cites W2093608891 @default.
• W4293506678 cites W2104465828 @default.
• W4293506678 cites W2114977186 @default.
• W4293506678 cites W2118577575 @default.
• W4293506678 cites W2126030533 @default.
• W4293506678 cites W2126924404 @default.
• W4293506678 cites W2128456060 @default.
• W4293506678 cites W2131841613 @default.
• W4293506678 cites W2143333241 @default.
• W4293506678 cites W2143498880 @default.
• W4293506678 cites W2146501335 @default.
• W4293506678 cites W2152573307 @default.
• W4293506678 cites W2158471822 @default.
• W4293506678 cites W2171885321 @default.
• W4293506678 cites W2616387367 @default.
• W4293506678 cites W2770441662 @default.
• W4293506678 cites W2779065393 @default.
• W4293506678 cites W2898820044 @default.
• W4293506678 cites W2921059814 @default.
• W4293506678 cites W2954843486 @default.
• W4293506678 cites W3007114385 @default.
• W4293506678 cites W3016522375 @default.
• W4293506678 cites W3031588991 @default.
• W4293506678 cites W3109974647 @default.
• W4293506678 cites W3135330360 @default.
• W4293506678 cites W4238822134 @default.
• W4293506678 cites W67192295 @default.
• W4293506678 cites W1997013607 @default.
• W4293506678 doi "https://doi.org/10.1093/jas/skac281" @default.
• W4293506678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36029013" @default.
• W4293506678 hasPublicationYear "2022" @default.
• W4293506678 type Work @default.
• W4293506678 citedByCount "2" @default.
• W4293506678 countsByYear W42935066782023 @default.
• W4293506678 crossrefType "journal-article" @default.
• W4293506678 hasAuthorship W4293506678A5004513507 @default.
• W4293506678 hasAuthorship W4293506678A5014354602 @default.
• W4293506678 hasAuthorship W4293506678A5025229697 @default.
• W4293506678 hasAuthorship W4293506678A5031577910 @default.
• W4293506678 hasAuthorship W4293506678A5033863509 @default.
• W4293506678 hasAuthorship W4293506678A5040460325 @default.
• W4293506678 hasAuthorship W4293506678A5075840871 @default.
• W4293506678 hasAuthorship W4293506678A5076742331 @default.
• W4293506678 hasAuthorship W4293506678A5085979296 @default.
• W4293506678 hasAuthorship W4293506678A5086907288 @default.
• W4293506678 hasAuthorship W4293506678A5091345962 @default.
• W4293506678 hasConcept C100817775 @default.
• W4293506678 hasConcept C126322002 @default.
• W4293506678 hasConcept C134018914 @default.
• W4293506678 hasConcept C140793950 @default.
• W4293506678 hasConcept C185592680 @default.
• W4293506678 hasConcept C206396517 @default.
• W4293506678 hasConcept C2775980262 @default.
• W4293506678 hasConcept C2776151105 @default.
• W4293506678 hasConcept C2776914184 @default.
• W4293506678 hasConcept C2778401633 @default.
• W4293506678 hasConcept C2779719659 @default.
• W4293506678 hasConcept C2779742124 @default.

• next